Eulav Asset Management Revance Therapeutics, Inc. Transaction History

Eulav Asset Management

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 30, 2024	SELL	$4.65 - $9.31 $604,500 - $1.21 Million	-130,000 Reduced 20.63%	500,000 $2.46 Million
Q4 2023 Feb 14, 2024	BUY	$5.81 - $11.2 $174,300 - $336,000	30,000 Added 5.0%	630,000 $5.54 Million
Q3 2023 Nov 13, 2023	BUY	$11.47 - $25.07 $5.05 Million - $11 Million	440,000 Added 275.0%	600,000 $6.88 Million
Q2 2023 Aug 09, 2023	BUY	$24.7 - $37.61 $1.36 Million - $2.07 Million	55,000 Added 52.38%	160,000 $4.05 Million
Q1 2023 Apr 27, 2023	SELL	$18.36 - $35.27 $1.19 Million - $2.29 Million	-65,000 Reduced 38.24%	105,000 $3.38 Million
Q4 2022 Feb 14, 2023	BUY	$18.32 - $30.66 $3.11 Million - $5.21 Million	170,000 New	170,000 $3.14 Million

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Eulav Asset Management, based on Form 13F filings with the SEC.

Stay updated on Eulav Asset Management with notifications on news.